直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Ex Parte Reexamination Stayed in Favor of Inter Partes Review

August 12, 2013

Authored and Edited by Timothy P. McAnulty; Anthony C. Tridico, Ph.D.

In a recent sua sponte order, the PTAB stayed a concurrent ex parte reexamination proceeding after another party filed a petition for inter partes review (IPR) against the same patent. Lumondi Inc. v. Lennon Image Tech., IPR2013-00432, Paper 7 (Aug. 6, 2013). The reexamination request was filed on September 15, 2012 and had already undergone substantial reexamination. The petition for inter partes review was filed almost a year later by a different party on July 10, 2013. Although the petition challenged substantially the same claims as the reexamination request, it raised different grounds of unpatentability based on different prior art.

The Board recognized that the Office does not ordinarily stay reexamination proceedings because they are to be conducted with special dispatch. According to the Board, however, conducting the two proceedings concurrently “would duplicate efforts within the Office and could potentially result in inconsistencies between the proceedings.” The Board provided three justifications for issue the stay. First, it noted that the patent owner could amend the claims in the reexamination proceeding separate from the inter parties review. Second, it emphasized the time constraints that apply to inter partes reviews. And third, it explained that decisions by the Board during the inter partes review may simplify the issues in the reexamination. The fact different parties challenged the claims based on different prior art “did not weigh in favor of concurrent Office proceedings” given the fact that the same claims were challenged in both proceedings.

In two other inter partes reviews, the PTAB denied motions that requested suspension of concurrent ex parte continuation applications under 37 CFR § 42.3. Chi Mei Innolux Corp. v. Semiconductor Energy Lab. Co., Ltd., IPR2013-00028, Paper 8 (Nov. 28, 2012); Chi Mei Innolux Corp. v. Semiconductor Energy Lab. Co., Ltd., IPR2013-00038, Paper 7 (Nov. 28, 2012). Rule 42.3 allows the Board to take exclusive jurisdiction over every involved application and patent during a proceeding. However, the Board explained that an “involved” patent is the patent in the proceeding and an “involved” application is an application subject to a derivation proceeding.

Thus, it seems likely that the PTAB will stay concurrent proceedings that directly relate to the patent actually challenged in the inter partes review, e.g., concurrent reexamination proceedings and perhaps reissue applications. And may similarly do so in post grant reviews and covered business method reviews. But the PTAB probably will not stay or suspend concurrent proceedings that are indirectly related to the challenged patent, e.g., pending ex parte continuation applications.

 

Tags

ex parte reexamination

Contacts

Timothy P. McAnulty
Partner
Washington, DC
+1 202 408 4348
Email
Anthony C. Tridico, Ph.D.
Partner
Washington, DC
+1 202 408 4173
Email

Copyright © 2013 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Lecture

Munich Licensing Summer Course 2026

June 18-19, 2026

Munich

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Articles

Article_D.-Mass-Patent-Litigation-Update-October-2024

D. Mass. Patent Litigation Update: April 2026

June 1, 2026

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP